Objective: Whether gastric atrophy (GA) and intestinal metaplasia (IM) are reversible after the eradication of Helicobacter pylori remains controversial. The purpose of this meta-analysis was to systematically review histological alterations in GA and IM by comparing histological scores before and after H. pylori eradication. Methods: English-language articles in the medical literature containing information about the association between infection with H. pylori and gastric premalignant lesions (i.e. GA and IM) were identified by searching the Medline, PubMed, and EMBASE databases with suitable key words up to December 2009. Review Manager 4.2.8 was used for the meta-analysis. Results: Twelve studies containing a total of 2,658 patients were included in the first meta-analysis. Before treatment, 2,648 patients had antrum GA, 2,401 patients had corpus GA, 2,582 patients had antrum IM, and 2,460 patients had corpus IM. Comparing the histological alterations before and after H. pylori eradication, the pooled weighted mean difference (WMD) with 95% CI for antral GA was 0.12 (0.00–0.23), p = 0.06. For corpus GA, the pooled WMD was 0.32 (0.09–0.54), p = 0.006. For antral IM, the pooled WMD was 0.02 (–0.12–0.16), p = 0.76, and for corpus IM, the pooled WMD was –0.02 (–0.05–0.02), p = 0.42. Conclusion: Our study shows that eradication of H. pylori results in significant improvement in GA in the corpus but not in the antrum; it also does not improve gastric mucous IM. Consequently, all patients with GA in the corpus should be tested for H. pylori infection, and eradication therapy should be prescribed for H. pylori-positive patients in those with GA in corpus.

Journal Section:
Original Paper
Keywords:
Helicobacter pylori, Gastric atrophy, Intestinal metaplasia, Eradication, Meta-analysis
1.
Parsonnet J: Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am 1993;22:89–104.
[PubMed]
2.
Yoshida S, Saito D: Gastric premalignancy and cancer screening in high risk patients. Am J Gastroenterol 1996, 91:839–843.
[PubMed]
3.
Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC Cancer Base No.5. Lyon, IARC Press, 2001.
4.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
[PubMed]
https://doi.org/10.3322%2Fcanjclin.55.2.74
5.
Buckley M, O’Morain C: Prevalence of in non-ulcer dyspepsia. Aliment Pharmacol Ther 1995;9(suppl):53–58.
6.
Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancer 1984;1:1311–1315.
[PubMed]
https://doi.org/10.1016%2FS0140-6736%2884%2991816-6
7.
Marshall BJ, Windsor HM: The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology epidemiology, screening clinical presentation treatment, and prevention. Med Clin North Am2005;89:313–344.
[PubMed]
https://doi.org/10.1016%2Fj.mcna.2004.09.001
8.
NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. NIH Consensus Development panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65–69.
https://doi.org/10.1001%2Fjama.272.1.65
9.
Parsonnet J, Hansen S, Rodriguez L, Gelb B, Warnke RA, Jellum E, Vogelman JH, Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J med 1994;330:1267–1271.
10.
Infection with Helicobactor pylori: IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, vol 61. Schistosomes, Liver Flukes, and Helicobactor pylori. Lyon, International Agency for Research on Cancer, 1994, pp 177–241.
11.
Ekstrom AM, Held M, Hansson LE, et al: Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001;121:784–791.
[PubMed]
https://doi.org/10.1053%2Fgast.2001.27999
12.
Brenner H, Arndt V, Stegmaier C, et al: Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004;159:252–258.
[PubMed]
https://doi.org/10.1093%2Faje%2Fkwh039
13.
Huang JQ, Sridhar S, Chen Y, et al: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterol 1998;114:1169–1179.
[PubMed]
https://doi.org/10.1016%2FS0016-5085%2898%2970422-6
14.
Helicobacter and Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347–353.
[PubMed]
https://doi.org/10.1136%2Fgut.49.3.347
15.
Correa P: Human gastric carcinogenesis: a multistep and multifactorial process-first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992;52:6735–6740.
[PubMed]
16.
Malfertheiner P, Sipponen P, Naumann M, et al: H. pylori-Gastric Cancer Task Force: Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100–2115.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2005.41688.x
17.
Chen X, Haruma K, Kamada T, et al: Factors that affect results of the 13C-urea breath test in Japanese patients. Helicobacter 2000;5:98–103.
[PubMed]
https://doi.org/10.1046%2Fj.1523-5378.2000.00015.x
18.
Price AB: The Sydney system: histological division. J Gastroenterol Hepatol 1991;6:209–222.
[PubMed]
https://doi.org/10.1111%2Fj.1440-1746.1991.tb01468.x
19.
Dixon MF, Genta RM, Yardley JH, et al: Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol 1996;20:1161–1181.
[PubMed]
https://doi.org/10.1097%2F00000478-199610000-00001
20.
Undertaking Systematic Reviews of Research on Effectiveness. CRD’s Guidance for Those Carrying Out or Commissioning Reviews. CRD Report No 4. University of York, Centre for Reviews and Dissemination, 2001.
21.
Iacopini F, Consolazio A, Bosco D, et al: Oxidative damage of the gastric mucosa in Helicabacter pylori positive chronic atrophic and nonatrophic gastritis, before and after eradication. Helicobacter 2003;8:503–512.
[PubMed]
https://doi.org/10.1046%2Fj.1523-5378.2003.00172.x
22.
Kamada T, Haruma K, Hata J, et al: The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 2003;18:245–252.
[PubMed]
https://doi.org/10.1046%2Fj.1365-2036.2003.01669.x
23.
Lu B, Chen MT, Fan YH, Liu Y, Meng LN: Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol 2005;11:6518–6520.
[PubMed]
24.
Sung JJ, Lin SR, Ching JY, et al: Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7–14.
[PubMed]
https://doi.org/10.1053%2Fgast.2000.8550
25.
Tucci A, Poli L, Tosetti C, et al: Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol 1998;93:1425–1431.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.1998.00454.x
26.
Ruiz B, Garav J, Correa P, et al: Morphometric evaluation of gastric antral atrophy: Improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001;96:3281–3287.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2001.05326.x
27.
Ito M, Haruma K, Kamada T, et al: Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449–1456.
[PubMed]
https://doi.org/10.1046%2Fj.1365-2036.2002.01311.x
28.
Kamada T, Hata J, Sugiu K, et al: Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005;21:1121–1126.
[PubMed]
https://doi.org/10.1111%2Fj.1365-2036.2005.02459.x
29.
Lahner E, Bordi C, Cattaruzza MS, et al: Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;22:471–481.
[PubMed]
https://doi.org/10.1111%2Fj.1365-2036.2005.02582.x
30.
Oda Y, Miwa J, Kaise M, et al: Five-year follow-up study on histological and endoscopic alterations in the gastric mucosa after Helicobacter pylori eradication. Dig Endosc 2004;16:213–218.
https://doi.org/10.1111%2Fj.1443-1661.2004.00360.x
31.
Wambura C, Nobuo A, Shirasaka D, et al: Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2004;16:969–979.
[PubMed]
https://doi.org/10.1097%2F00042737-200410000-00004
32.
Toyokawa T, Suwaki K, Miyake Y, et al: Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol 2010;25:434–435.
[PubMed]
https://doi.org/10.1111%2Fj.1440-1746.2009.05995.x
33.
Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
[PubMed]
https://doi.org/10.1016%2F0197-2456%2895%2900134-4
34.
Zhou L, Sung JJ, Lin S, et al: A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003;116:11–14.
[PubMed]
35.
Leung WK, Lin SR, Ching JY, et al: Factors predicting progression of gastric intestinal metaplasia: results of a randomized trial on Helicobacter pylori eradication. Gut 2004;53:1244–1249.
[PubMed]
https://doi.org/10.1136%2Fgut.2003.034629
36.
Mera R, Fontham ET, Bravo LE, et al: Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536–1540.
[PubMed]
https://doi.org/10.1136%2Fgut.2005.072009
37.
You WC, Brown LM, Zhang L, et al: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974–983.
[PubMed]
https://doi.org/10.1093%2Fjnci%2Fdjj264
38.
Rokkas T, Pistiolas D, Sechopoulos P, et al: The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007;12:32–38.
[PubMed]
https://doi.org/10.1111%2Fj.1523-5378.2007.00563.x
39.
Moayyedi P: Meta-analysis: can we mix apples and oranges? Am J Gastroenterol 2004;99:2297–2301.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2004.40948.x
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.